Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Canada
/
Pharmaceuticals & Biotech
/
HLS Therapeutics
HLS
HLS Therapeutics
Price Controls And Generics Will Erode Future Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
14 Aug 25
Updated
14 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
CA$3.86
31.5% overvalued
intrinsic discount
14 Aug
CA$5.08
Loading
1Y
59.1%
7D
0.9%
Author's Valuation
CA$3.9
31.5% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
CA$3.9
31.5% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-26m
71m
2015
2017
2019
2021
2023
2025
2027
2028
Revenue US$65.2m
Earnings US$415.9k
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
6.12%
Pharma revenue growth rate
1.05%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
5.97%
Calculation
US$415.87k
Earnings '28
x
240.01x
PE Ratio '28
=
US$99.81m
Market Cap '28
US$99.81m
Market Cap '28
/
31.16m
No. shares '28
=
US$3.20
Share Price '28
US$3.20
Share Price '28
Discounted to 2025 @ 5.97% p.a.
=
US$2.69
Fair Value '25
US$2.69
Fair Value '25
Converted to CAD @ 1.3807 USD/CAD Exchange Rate
=
CA$3.71
Fair Value '25
